Study of AMV564 in Patients With AML
This is a first in human, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of AMV564.
Acute Myeloid Leukemia
BIOLOGICAL: AMV564|COMBINATION_PRODUCT: AMV564 in combination with pembrolizumab
Dose escalation + expansion stage: incidence of all adverse events and serious adverse events (safety and tolerability), Number of participants with adverse events as a measure of safety and tolerability., 42 months|Expansion stage: Efficacy - Remission Rate, Proportion of participants who achieve complete remission, complete remission with incomplete recovery or partial remission, 42 months
This study is a first in human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D to evaluate the safety, tolerability and preliminary antileukemic activity of AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML).

AMV564 will be given on Days 1-14 of a 4-week cycle, or Days 1-28 of a 6-week cycle,via CIV or subcutaneous administration for 1 or more treatment cycles as monotherapy or in combination with pembrolizumab.